Random bits

Pfizer’s 2010 Financial Report for investors covers a number of topics.

Where does Pfizer sell its drugs? The U.S. represented 42.8 percent of Pfizer’s 2010 sales. Western Europe and Scandinavian countries were 24.6 percent. Australia, New Zealand, Canada, Japan, and South Korea were 14.9 percent. Together, these high income countries were 82.3 percent of Pfizer’s 2010 sales.

Pfizer calls the other Asian countries, plus Africa, Latin America, and Eastern Europe, “emerging markets.” This segment had 17.7 percent of Pfizer sales in 2010, up from 14.9 percent in 2008. In 2010, the “emerging markets” were 72 percent of the sales in Western Europe and Scandinavia, and growing at a faster rate. Read the rest of this entry »

As Chairman of the Council of Economic Advisers, and in various other roles as a close adviser to Obama, Austan Goolsbee was thought of as an influential member of the Obama Administration. What will change now that he is leaving? These are just a few data points from his recent and not so recent past.

In an interview with John Stewart last week, Goolsbee referred to the various bilateral free trade agreements as part of a bipartisan consensus of things to promote U.S. jobs.

In a 2008 flap about Obama’s real views on trade policy, and with regard to NAFTA in particular, Goolsbee was a campaign aide, and was caught assuring Canadian officials that “Mr. Obama’s protectionist stand on the trail was ‘more reflective of political maneuvering than policy.’” http://www.nytimes.com/2008/03/04/us/politics/04nafta.html Read the rest of this entry »

In 1997, the Orphan Drug Tax Credit was made permanent. In 1998, $80.4 million in credits were claimed on tax returns. By 2008, the claimed credits totaled $450.2 million. This represents a compound growth rate of 17 percent per year. Over the eleven year period, the IRS reported total credits of $2.3355 billion. This is not much when you consider that the orphan tax credit covers 50 percent of the cost of qualifying clinical trials. During the period from January 1, 1997 to December 31, 2008, the FDA granted 1163 orphan designations for which the credit applied. In the same period, the FDA gave marketing approval to 183 indications. On a per-approval basis, that works out to 2335.5/183 = $12.8 million per indication that received FDA marketing approval.

It is also useful to note that there were 6.4 indications for each one receiving marketing approval — a useful statistic regarding the hazard rate for orphan products. Read the rest of this entry »

Today Paul Miano published this report: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines, KEI Research Note 2011:1.

One of the findings of the report: ownership of cancer drugs sold as a monopoly is concentrated in six countries. And, 85 percent of patented cancer drugs are owned by firms from the US, the UK and Switzerland. Read the rest of this entry »

Before Google Plus, I spent a fair amount of time updating Facebook and twitter. Since Google Plus became available, I initially have found myself focusing less on twitter. I don’t make much use of the G+ circles, but I do like the ability to follow people and comment on their posts, and have people comment on mine. I also like the fact that I am not bound by limits on the number of characters I enter, even though I initially thought this would be a negative.

I have used a blackberry for some time, mostly to get inexpensive email from T-Mobile when I travel outside of the USA. This week I spent $150 from Amazon to buy the Samsung Galaxy Prevail, which is a smartphone that relies upon the Boost Mobile/Sprint CDMA network, running the Android 2.2 OS. It is a very nice phone for the money, and I’m kind of astonished at how much you can do with it. I still have my other phone, so I put it on a pay as you go plan with Boost Mobile, for $2 on the days I use it, and zero when I don’t. Now I’m wondering how I can live without the Blackberry email when I travel outside the US.

I have moved this post to the new URL for Random Bits. The current link for this blog entry is:
http://randombits.workingagenda.com/node/12

I use Ubuntu, and like some Adobe AIR applications, like the Adobe AIR implementation of Tweetdeck, so this is a disappointment.

This now from Adobe: “Beginning June 14 2011, Adobe AIR is no longer supported for desktop Linux distributions. . . . Lifetime AIR for Linux desktop downloads represent less than 0.5% of total AIR desktop downloads, which number over 450 million. Therefore, Adobe has decided to change the distribution model for Linux and direct these resources toward its mobile efforts. Adobe’s efforts are focused on supporting operating systems that are most important to its customers, and that demonstrate the greatest opportunity for future growth for our partners and developers.”

This is a playlist I created at Grooveshark last March. I’m not sure how they do this, in terms of legal issues.
http://grooveshark.com/#/playlist/20110312/50324881 Read the rest of this entry »

After experiencing a lot of frustration with my work computer freezing up, I bought a new Gateway FX6860, tested it home over the weekend (my evaluation here), and brought it to work today. But at the office, the new computer had exactly the same issues as the old one. Read the rest of this entry »